36
total announcements
539730.BO · 15 min delayed
Fredun Pharmaceuticals Ltd
Fredun Pharmaceuticals Ltd has announced an earnings conference call for Q2 of FY27, to be held on November 16, 2026, at 12:00 p.m. The conference call details include dial-in numbers and a registration link.
Fredun Pharmaceuticals Ltd
Fredun Pharmaceuticals Ltd publishes un-audited financial results for Q2 and H1 FY2026-27 in compliance with SEBI Listing Regulations.
Fredun Pharmaceuticals Ltd
Fredun Pharmaceuticals Ltd reported a 94% YoY growth in net profit, 92% YoY growth in EBITDA, and 87% YoY growth in revenue for H1 FY27. The company's diversified portfolio spans generics, cosmeceuticals, nutraceuticals, mobility solutions, and animal healthcare products. Key business highlights include the acquisition of Furlicks, a 26% stake in Goodman Vetcare, and the launch of PAWTALKS as a pet healthcare knowledge platform.
Fredun Pharmaceuticals Ltd
Fredun Pharmaceuticals Ltd has announced its unaudited financial results for the quarter and half-year ended September 30, 2026, along with the Limited Review Report by its statutory auditor, R.H. Nisar & Co. The company has also announced its intention to list on the National Stock Exchange of India (NSE).
Fredun Pharmaceuticals Ltd
Fredun Pharmaceuticals Ltd has announced its revised outcome of the board meeting dated 05th November, 2026. The company has considered and approved the proposal for making an application to National Stock Exchange of India Limited (NSE) for listing and trading of the equity shares of the company on NSE, subject to applicable laws, regulations, and necessary approvals. The company has also submitted its standalone unaudited quarterly financial results for the quarter ended 30th September, 2026, along with the limited review report issued by its statutory auditor.
Fredun Pharmaceuticals Ltd
Fredun Pharmaceuticals Ltd has announced that its Board of Directors has approved a proposal to list on the National Stock Exchange of India Limited (NSE) and has also approved its unaudited financial results for the quarter ended September 30, 2026.
Fredun Pharmaceuticals Ltd
Fredun Pharmaceuticals Ltd has announced its financial results for the quarter ended 30th September, 2026, with the company's board of directors approving the unaudited financial results and a proposal to list on the National Stock Exchange (NSE). The results show that the company has not disclosed any material misstatements or omissions. The company's management has prepared the financial statements in accordance with Indian Accounting Standard 34 and other accounting principles generally accepted in India.
Fredun Pharmaceuticals Ltd
Fredun Pharmaceuticals Ltd has announced its unaudited financial results for the quarter and half-year ended 30th September 2026, along with the Limited Review Report by its statutory auditor. The company has also approved a proposal to list its equity shares on the National Stock Exchange (NSE).
Fredun Pharmaceuticals Ltd
Fredun Pharmaceuticals Ltd has informed BSE that the meeting of the Board of Directors is scheduled on 05/11/2026 to consider and approve Unaudited Standalone and Consolidated Financial Results for the Quarter and Half Year ended September 30, 2026.
Fredun Pharmaceuticals Ltd
Fredun Pharmaceuticals Ltd has allotted 44,000 equity shares to non-promoter allottees pursuant to the conversion of 14,667 warrants into equity shares, consequent to the 1:2 bonus issue. The allotment was made in dematerialized form, and the equity shares will rank pari passu with the existing equity shares of the company in all respects.
Fredun Pharmaceuticals Ltd
Fredun Pharmaceuticals Ltd has allotted 44,000 equity shares to non-promoter allottees upon conversion of 14,667 warrants into equity shares, following a 1:2 bonus issue.
Fredun Pharmaceuticals Ltd
Fredun Pharmaceuticals Ltd has submitted a certificate pursuant to Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, confirming the dematerialization of securities for the quarter ended September 30, 2026.
Fredun Pharmaceuticals Ltd
Fredun Pharmaceuticals Ltd, a conventional manufacturing-led pharmaceutical company, is transforming into a brand-led healthcare platform with a focus on pet healthcare, premium wellness, and specialty therapeutics. The company has made strategic investments in Goodman Vetcare, Furlicks, and WAGR, and plans to transition to a 100% branded portfolio by 2029, with a target of doubling revenue and profitability over the next 3-4 years.
Fredun Pharmaceuticals Ltd
Fredun Pharmaceuticals Ltd has allotted 1,82,400 equity shares to non-promoter allottees upon conversion of 60,800 warrants into equity shares, following the 1:2 bonus issue.
Fredun Pharmaceuticals Ltd
Fredun Pharmaceuticals Ltd has allotted 1,82,400 equity shares to non-promoter allottees pursuant to the conversion of 60,800 warrants into equity shares, consequent to the 1:2 bonus issue.
Fredun Pharmaceuticals Ltd
Fredun Pharmaceuticals Ltd has allotted 1,82,400 equity shares to non-promoter allottees pursuant to the conversion of 60,800 warrants into equity shares, consequent to the 1:2 bonus issue.
Fredun Pharmaceuticals Ltd
Fredun Pharmaceuticals Ltd has allotted 1,82,400 equity shares to non-promoter allottees pursuant to the conversion of 60,800 warrants into equity shares, consequent to the 1:2 bonus issue.
Fredun Pharmaceuticals Ltd
Fredun Pharmaceuticals Ltd has announced the closure of the trading window for its designated persons and their immediate relatives from October 1, 2026, until 48 hours after the Board Meeting where the unaudited Financial Results for the quarter and half year ended September 30, 2026, will be considered, approved, and declared.
Fredun Pharmaceuticals Ltd
Fredun Pharmaceuticals Ltd has allotted 3,61,599 equity shares to non-promoter allottees pursuant to the conversion of 1,20,533 warrants into equity shares, consequent to the 1:2 bonus issue.
Fredun Pharmaceuticals Ltd
Fredun Pharmaceuticals Ltd has allotted 3,61,599 equity shares to non-promoter allottees pursuant to the conversion of 1,20,533 warrants into equity shares, consequent to the 1:2 bonus issue.